Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-alpha in the community

Joint Bone Spine

Volumn 73, Issue 1, 2006, Pages 51-56

  Genta, Marcia S ^a   Kardes, Hakan ^a   Gabay, Cem ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Anti TNF agents; Community based study; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CHICKENPOX; CLINICAL EXAMINATION; DATA BASE; DEMOGRAPHY; DISEASE ACTIVITY; FELTY SYNDROME; FEMALE; FUNCTIONAL STATUS; HEART INFARCTION; HUMAN; LABORATORY TEST; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALAISE; MALE; METASTASIS; MYALGIA; NAUSEA; PAIN ASSESSMENT; PRURITUS; RADIOLOGY; RASH; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SINUSITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PAIN MEASUREMENT; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 32044434737     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2005.07.002     Document Type: Article

References (23)

1. J.R. O'Dell Anticytokine therapy - a new era in the treatment of rheumatoid arthritis? N. Engl. J. Med. 340 1999 310 312
2. N.J. Olsen, and C.M. Stein New drugs for rheumatoid arthritis N. Engl. J. Med. 350 2004 2167 2179
3. M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, and R.I. Fox A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N. Engl. J. Med. 340 1999 253 259
4. P.E. Lipsky, D.M. van der Heijde, E.W. St Clair, D.E. Furst, F.C. Breedveld, and J.R. Kalden Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N. Engl. J. Med. 343 2000 1594 1602
5. M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, and C.A. Birbara Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial Arthritis Rheum. 48 2003 35 45
6. L. Klareskog, H.D. van der, J.P. de Jager, A. Gough, J. Kalden, and M. Malaise Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 2004 675 681
7. J.R. O'Dell Therapeutic strategies for rheumatoid arthritis N. Engl. J. Med. 350 2004 2591 2602
8. E. Uitz, J. Fransen, T. Langenegger, and G. Stucki Clinical quality management in rheumatoid arthritis: putting theory into practice. Swiss Clinical Quality Management in Rheumatoid Arthritis Rheumatology (Oxford) 39 2000 542 549
9. R. Rau, S. Wassenberg, G. Herborn, G. Stucki, and A. Gebler A new method of scoring radiographic change in rheumatoid arthritis J. Rheumatol. 25 1998 2094 2107
10. M.L. Prevoo, M.A. 't Hof, H.H. Kuper, M.A. van Leeuwen, L.B. van de Putte, and P.L. van Riel Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis Arthritis Rheum. 38 1995 44 48
11. D. Wendling, G.E. Materne, F. Michel, A. Lohse, G. Lehuede, and E. Toussirot Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice Joint Bone Spine 72 2005 309 312
12. A. Finckh Are there differences in the ability of infliximab and etanercept to prevent structural joint damage in rheumatoid arthritis? Arthritis Rheum. S333 2003 48
13. R. Maini, E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, and M. Weisman Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group Lancet 354 1999 1932 1939
14. J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, and W.D. Schwieterman Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N. Engl. J. Med. 345 2001 1098 1104
15. R. Day Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis Lancet 359 2002 540 541
16. S. Kroesen, A.F. Widmer, A. Tyndall, and P. Hasler Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy Rheumatology (Oxford) 42 2003 617 621
17. H. Maillard, P. Ornetti, L. Grimault, J.F. Ramon, S. Melac Ducamp, and T. Saidani Severe pyogenic infections in patients taking infliximab. A regional cohort study Joint Bone Spine 72 2005 330 334
18. F. Bobbio-Pallavicini, C. Alpini, R. Caporali, S. Avalle, S. Bugatti, and C. Montecucco Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment Arthritis Res. Ther. 6 2004 264 272
19. Y. Allanore, J. Sellam, F. Batteux, D.C. Job, B. Weill, and A. Kahan Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab Clin. Exp. Rheumatol. 22 2004 756 758
20. D.P. Symmons, and A.J. Silman Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer Arthritis Rheum. 50 2004 1703 1706
21. F. Wolfe, and K. Michaud Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients Arthritis Rheum. 50 2004 1740 1751
22. B. Hernandez-Cruz, and M.H. Cardiel Intra-observer reliability of commonly used outcome measures in rheumatoid arthritis Clin. Exp. Rheumatol. 16 1998 459 462
23. D.L. Scott, E.H. Choy, A. Greeves, D. Isenberg, D. Kassinor, and E. Rankin Standardising joint assessment in rheumatoid arthritis Clin. Rheumatol. 15 1996 579 582